{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:33:06Z","timestamp":1768037586189,"version":"3.49.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S00081X\/1"],"award-info":[{"award-number":["MR\/S00081X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["GSK-Varsity Initiative award"],"award-info":[{"award-number":["GSK-Varsity Initiative award"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2020.00329","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T04:47:27Z","timestamp":1593665247000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?"],"prefix":"10.3389","volume":"10","author":[{"given":"Ian J.","family":"Groves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Wills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.3389\/fmicb.2019.03060","article-title":"Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs","volume":"10","author":"Ait-Ammar","year":"2019","journal-title":"Front. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.chom.2017.03.007","article-title":"Transcriptional elongation of HSV immediate early genes by the super elongation complex drives lytic infection and reactivation from latency","volume":"21","author":"Alfonso-Dunn","year":"2017","journal-title":"Cell Host Microbe"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1074\/mcp.M116.065375","article-title":"Kinome profiling identifies druggable targets for novel human cytomegalovirus (HCMV) antivirals","volume":"16","author":"Arend","year":"2017","journal-title":"Mol. Cell. Proteomics"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511545313","volume-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","author":"Arvin","year":"2007"},{"key":"B5","doi-asserted-by":"publisher","first-page":"36609","DOI":"10.1074\/jbc.M112.410746","article-title":"Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein","volume":"287","author":"Bartholomeeusen","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B6","first-page":"504","article-title":"Bromodomain inhibitors: what does the future hold?","volume":"16","author":"Bhattacharya","year":"2018","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1742-4690-4-47","article-title":"Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex","volume":"4","author":"Biglione","year":"2007","journal-title":"Retrovirology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1172\/JCI80565","article-title":"Molecular mechanisms of HIV latency","volume":"126","author":"Cary","year":"2016","journal-title":"J. Clin. Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41580-018-0010-5","article-title":"Born to run: control of transcription elongation by RNA polymerase II","volume":"19","author":"Chen","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1006100","DOI":"10.1371\/journal.ppat.1006100","article-title":"BET-inhibitors disrupt Rad21-dependent conformational control of KSHV latency","volume":"13","author":"Chen","year":"2017","journal-title":"PLoS Pathog"},{"key":"B11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.coviro.2013.03.004","article-title":"Epigenetic regulation of EBV and KSHV latency","volume":"3","author":"Chen","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1099\/jgv.0.000594","article-title":"BRD4 is associated with raccoon polyomavirus genome and mediates viral gene transcription and maintenance of a stem cell state in neuroglial tumour cells","volume":"97","author":"Church","year":"2016","journal-title":"J. Gen. Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.coviro.2019.08.003","article-title":"Cytomegalovirus is a tumor-associated virus: armed and dangerous","volume":"39","author":"Cobbs","year":"2019","journal-title":"Curr. Opin. Virol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","article-title":"Bromodomains: a new target class for drug development","volume":"18","author":"Cochran","year":"2019","journal-title":"Nat. Rev. Drug Discov"},{"key":"B15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrd1065","article-title":"Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets","volume":"2","author":"Coen","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tim.2019.09.002","article-title":"Control of viral latency by episome maintenance proteins","volume":"28","author":"De Leo","year":"2020","journal-title":"Trends Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/infdis\/jiz577","article-title":"Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients","volume":"221","author":"Douglas","year":"2020","journal-title":"J. Infect. Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-barr virus and cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu. Rev. Pathol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/bmb\/ldt011","article-title":"Recent developments in anti-herpesvirus drugs","volume":"106","author":"Field","year":"2013","journal-title":"Br. Med. Bull"},{"key":"B21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/onc.2015.245","article-title":"Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors","volume":"35","author":"Gopalakrishnan","year":"2016","journal-title":"Oncogene"},{"key":"B24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"Halper-Stromberg","year":"2014","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-3-319-22822-8_6","article-title":"The epigenetic life cycle of epstein-barr virus","volume":"390","author":"Hammerschmidt","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/v10080408","article-title":"The human cytomegalovirus, from oncomodulation to oncogenesis","volume":"10","author":"Herbein","year":"2018","journal-title":"Viruses"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1007267","DOI":"10.1371\/journal.ppat.1007267","article-title":"Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency","volume":"14","author":"Hopcraft","year":"2018","journal-title":"PLoS Pathog"},{"key":"B28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1128\/JVI.01681-07","article-title":"Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome","volume":"82","author":"Kapasi","year":"2008","journal-title":"J. Virol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13284","DOI":"10.1074\/jbc.M116.751644","article-title":"Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps","volume":"292","author":"Keck","year":"2017","journal-title":"J. Biol. Chem"},{"key":"B30","doi-asserted-by":"publisher","first-page":"24674","DOI":"10.1038\/srep24674","article-title":"Transient activation of human cytomegalovirus lytic gene expression during latency allows cytotoxic T cell killing of latently infected cells","volume":"6","author":"Krishna","year":"2016","journal-title":"Sci. Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldz031","article-title":"Advances in the treatment of cytomegalovirus","volume":"131","author":"Krishna","year":"2019","journal-title":"Br. Med. Bull"},{"key":"B32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.virol.2015.01.026","article-title":"Dynamic modulation of HSV chromatin drives initiation of infection and provides targets for epigenetic therapies","volume":"480","author":"Kristie","year":"2015","journal-title":"Virology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41419-018-0789-1","article-title":"BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"12009","DOI":"10.1128\/JVI.01680-08","article-title":"The EBNA1 protein of Epstein-Barr virus functionally interacts with Brd4","volume":"82","author":"Lin","year":"2008","journal-title":"J. Virol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"24100","DOI":"10.1038\/srep24100","article-title":"The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb","volume":"6","author":"Lu","year":"2016","journal-title":"Sci. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1006\/jmbi.1995.0152","article-title":"Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses","volume":"247","author":"McGeoch","year":"1995","journal-title":"J. Mol. Biol."},{"key":"B37","first-page":"375","article-title":"Molecular biology of animal herpesviruses","volume-title":"Animal Viruses: Molecular Biology","author":"Mettenleiter","year":"2008"},{"key":"B38","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1021\/jm401088k","article-title":"Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains","volume":"56","author":"Mirguet","year":"2013","journal-title":"J. Med. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13148-019-0654-9","article-title":"Control of viral infections by epigenetic-targeted therapy","volume":"11","author":"Nehme","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1172\/JCI120633","article-title":"Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV","volume":"129","author":"Niu","year":"2019","journal-title":"J. Clin. Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"C244","DOI":"10.1158\/1535-7163.TARG-13-C244","article-title":"Development of the BET bromodomain inhibitor OTX015","volume":"12","author":"Noel","year":"2013","journal-title":"Mol. Cancer Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1002334","DOI":"10.1371\/journal.ppat.1002334","article-title":"RNA polymerase II stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus","volume":"7","author":"Palermo","year":"2011","journal-title":"PLoS Pathog."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-12-3292","article-title":"PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains","volume":"73","author":"Picaud","year":"2013","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1093\/infdis\/jiz448","article-title":"Preventing infection by human cytomegalovirus","volume":"221","author":"Plotkin","year":"2020","journal-title":"J. Infect. Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"313761","DOI":"10.1155\/2014\/313761","article-title":"Human cytomegalovirus latency: targeting differences in the latently infected cell with a view to clearing latent infection","volume":"2014","author":"Poole","year":"2014","journal-title":"New J. Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"ofz375","DOI":"10.1093\/ofid\/ofz375","article-title":"Emergence and persistence of letermovir-resistant cytomegalovirus in a patient with primary immunodeficiency","volume":"6","author":"Popping","year":"2019","journal-title":"Open Forum Infect. Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1005950","DOI":"10.1371\/journal.ppat.1005950","article-title":"An epigenetic compound library screen identifies BET inhibitors that promote HSV-1 and\u22122 replication by bridging P-TEFb to viral gene promoters through BRD4","volume":"12","author":"Ren","year":"2016","journal-title":"PLoS Pathog."},{"key":"B49","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.bbagrm.2009.08.001","article-title":"Chromatin structure regulates human cytomegalovirus gene expression during latency, reactivation and lytic infection","volume":"1799","author":"Sinclair","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1099\/vir.0.81891-0","article-title":"Latency and reactivation of human cytomegalovirus","volume":"87","author":"Sinclair","year":"2006","journal-title":"J. Gen. Virol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.3390\/v5112803","article-title":"Human cytomegalovirus manipulation of latently infected cells","volume":"5","author":"Sinclair","year":"2013","journal-title":"Viruses"},{"key":"B52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1182\/blood.V128.22.46.46","article-title":"BET bromodomain inhibition selectively targets the epstein-barr virus oncogene LMP1 while promoting virus-specific, adaptive anti-tumor activity","volume":"128","author":"Smith","year":"2016","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(07)70267-3","article-title":"The neurotropic herpes viruses: herpes simplex and varicella-zoster","volume":"6","author":"Steiner","year":"2007","journal-title":"Lancet Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s12879-017-2683-3","article-title":"Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing","volume":"17","author":"Thorlund","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1038\/onc.2013.242","article-title":"Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors","volume":"33","author":"Tolani","year":"2014","journal-title":"Oncogene"},{"key":"B56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/v12010084","article-title":"Block-and-lock strategies to cure HIV infection","volume":"12","author":"Vansant","year":"2020","journal-title":"Viruses"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e1008429","DOI":"10.1371\/journal.ppat.1008429","article-title":"BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses","volume":"16","author":"Wang","year":"2020","journal-title":"PLoS Pathog"},{"key":"B58","doi-asserted-by":"publisher","first-page":"10738","DOI":"10.1074\/jbc.M111.323493","article-title":"Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure","volume":"287","author":"Wang","year":"2012","journal-title":"J. Biol. Chem"},{"key":"B59","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.16157.1","article-title":"Clinical management of herpes simplex virus infections: past, present, and future","volume":"7","author":"Whitley","year":"2018","journal-title":"F1000Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/cmi.2014.75","article-title":"The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?","volume":"12","author":"Wills","year":"2015","journal-title":"Cell. Mol. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"B62","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/s41594-019-0309-8","article-title":"Bromodomain biology and drug discovery","volume":"26","author":"Zaware","year":"2019","journal-title":"Nat. Struct. Mol. Biol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1158\/1535-7163.MCT-17-0041","article-title":"Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma","volume":"16","author":"Zhou","year":"2017","journal-title":"Mol. Cancer Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.chom.2014.12.013","article-title":"Epstein-Barr virus oncoprotein super-enhancers control B cell growth","volume":"17","author":"Zhou","year":"2015","journal-title":"Cell Host Microbe"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T04:47:31Z","timestamp":1593665251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":64,"alternative-id":["10.3389\/fcimb.2020.00329"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2020.00329","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"article-number":"329"}}